Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 5/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | EED | O75530 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21634620 | 0.87 | PTPN11 (0.43) | PIM1PIM2PTPN11BRD4L3MBTL1 | |
| SCHEMBL19320342 | 0.85 | PIM1 (0.40) | PIM1PIM2PTPN11BRD4L3MBTL1 | |
| SCHEMBL2132380 | 0.85 | PTPN11 (0.41) | PIM1PIM2PTPN11BRD4L3MBTL1 | |
| SCHEMBL19325113 | 0.84 | PIM1 (0.40) | PIM1PIM2PTPN11BRD4L3MBTL1 | |
| SCHEMBL20016711 | 0.76 | BRD4 (0.32) | BRD4 | |
| SCHEMBL19325294 | 0.76 | BRD4 (0.35) | PIM1PIM2BRD4 | |
| SCHEMBL19325201 | 0.76 | PIM1 (0.41) | PIM1PIM2PTPN11BRD4NTRK1 | |
| SCHEMBL19320338 | 0.76 | BRD4 (0.35) | PIM1PIM2BRD4 | |
| SCHEMBL31246045 | 0.76 | HTR6 (0.48) | PTPN11L3MBTL1GBA1NTRK1POLB | |
| SCHEMBL16728464 | 0.74 | PTPN11 (0.43) | PIM1PIM2PTPN11BRD4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932346-B2 | Pyrrolopyrimidines for use in influenza virus infection | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-03 | — | — | US | disclosed |
| US-20170253600-A1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-09-07 | — | — | US | disclosed |
| US-20170253600-A1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253600-A1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | IMPDH1, IMPDH2, TYMP | PIM1 480/4885PIM2 606/4885PTPN11 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.